Bank of Montreal
ALLO icon

Bank of Montreal’s Allogene Therapeutics ALLO Stock Holding History

Bank of Montreal’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-27,827
Closed -$428K – 4137
2021
Q4 		$428K Buy
+27,827
New +$491K ﹤0.01% 2510
2021
Q2 		– Sell
-2,644
Closed -$89K – 3667
2021
Q1 		$89K Sell
2,644
-5,711
-68% -$193K ﹤0.01% 3444
2020
Q4 		$234K Buy
8,355
+5,852
+234% +$191K ﹤0.01% 3142
2020
Q3 		$98K Sell
2,503
-1,377
-35% -$51.9K ﹤0.01% 3083
2020
Q2 		$171K Buy
+3,880
New +$140K ﹤0.01% 2813
2020
Q1 		– Sell
-4,880
Closed -$127K – 4064
2019
Q4 		$127K Buy
4,880
+1,478
+43% +$40.7K ﹤0.01% 3390
2019
Q3 		$93K Buy
3,402
+179
+6% +$5.1K ﹤0.01% 3336
2019
Q2 		$87K Buy
+3,223
New +$89.8K ﹤0.01% 3418

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Bank of Montreal's ALLO Position: Q1 2022 in Review

Bank of Montreal sold out of Allogene Therapeutics (ALLO) in Q1 2022, closing a stake of 27,827 shares — an estimated $428K sold.

Bank of Montreal first reported a position in ALLO in Q2 2019 and held it in 8 quarters. The position peaked at $428K in Q4 2021. 180 funds tracked by Wall St. Rank hold ALLO as of Q1 2022.

  • Bank of Montreal reported no remaining Allogene Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Bank of Montreal sold 27,827 Allogene Therapeutics shares in Q1 2022, an estimated $428K.
  • Bank of Montreal first reported a position in Allogene Therapeutics in Q2 2019 and held it in 8 quarters.
  • Bank of Montreal's Allogene Therapeutics position peaked at $428K in Q4 2021.
  • 180 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2022.

Based on Bank of Montreal's 13F filing for Q1 2022, filed 12 May 2022.